GSK Divests Two Travel Vaccines

GSK Divests Two Travel Vaccines

by | Oct 28, 2019 2:17 pm | Biotechnology, Pharmaceuticals | 0 comments

GlaxoSmithKline plc (NYSE: GSK) announced recently it is selling two travel vaccines to Bavarian Nordic for $334.7 million upfront, plus a potential $1.06 billion in milestone payments. The sale included rabies vaccine Rabipur (tradename Rabavert in the United States) and Encepur, for the prevention of tick-borne encephalitis. GSK obtained the vaccines as part of a 2015 deal with Novartis (NYSE: NVS). GSK divested its oncology business to Novartis for $300 million and gained the vaccines in return. According to the company’s annual report, GSK generated $7.58 billion from its vaccine segment in 2018. Both vaccines will continue to be manufactured primarily at GSK’s Marburg site in... Read More »